Home / Health / Pfizer Cancer Drug Shows 40% Risk Reduction
Pfizer Cancer Drug Shows 40% Risk Reduction
18 Mar
Summary
- Experimental drug combo reduced disease progression or death by 40%.
- Tested on advanced breast cancer patients who previously received treatment.
- Drug had a manageable safety profile with few treatment discontinuations.
An experimental drug combination from Pfizer, featuring atirmociclib with fulvestrant hormone therapy, has demonstrated a notable 40% reduction in the risk of disease progression or death in breast cancer patients. This finding emerged from a mid-stage study involving individuals with advanced cancer who had previously undergone treatment.
The study specifically enrolled patients whose cancer returned shortly after receiving widely used CDK4/6 drugs, a demographic known to be more challenging to treat. Importantly, more than 90% of these participants initiated treatment with atirmociclib within three months of concluding their prior cancer medication.
Pfizer reported that the drug combo exhibited a manageable safety profile. Treatment was discontinued due to side effects in only 6.4% of patients. While overall survival data is still being gathered, these results are encouraging and support further investigation of atirmociclib in earlier stages of breast cancer treatment.
